Skip to content

MHRA provides further guidance on no-deal Brexit plans

Related people
Jacqueline Bore

Senior PSL / Life Sciences

London

View profile →

14 January 2019

The MHRA has issued updated guidance on its plans for the regulation of medicines, medical devices and clinical trials in the event that the United Kingdom leaves the European Union on 29 March 2019 without any agreement on its future relationship with the EU and, therefore, without any transitional period. The guidance reflects responses to the government consultation conducted in the Autumn of last year and will be enacted into UK law in time for a no-deal exit by amendments to the relevant statutory instruments.

Related expertise